newsfilter
← Earnings
Earnings Releases·

Kardigan — Third Quarter 2026 Earnings Summary

  • **Financial Results:** Net loss narrowed to $58.6 million (vs. $60.2 million prior year) with improved net loss per share of $0.64 (vs. $4.43); cash and investments rose to $591.4 million following the June 2026 IPO, while R&D and G&A expenses increased to $64.4 million and $22.2 million respectively.
  • **Strategic Milestones:** Completed IPO in June 2026, eliminating preferred stock and converting total stockholders' equity from a $250.3 million deficit to $572.5 million; appointed Kristin Reinke to the Board and Audit Committee in September 2026.
  • **Clinical Outlook:** Topline data expected in 2027 for Phase 2b KINSHIP-DCM (Q2), Phase 2 KARDINAL-ASH (H2), and Phase 2b KATALYST-AV (H2), with a Phase 3 ataciguat update anticipated in H1 2027.
  • **Future Outlook:** Management confirms cash runway supports advancing all three programs through clinical readouts and Phase 3 initiation, citing confidence in delivering "value-inflecting data" in 2027.
Company
KARDIGAN INC
Sector
Healthcare
Industry
Biotechnology